Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POSIMIR vs ALPHACAINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bupivacaine, the active ingredient in POSIMIR, is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. POSIMIR is a bupivacaine extended-release liposomal formulation designed for sustained release at the surgical site.
Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.
Single-dose administration in adults for local analgesia at the surgical site following bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty (TKA).
Local anesthesia by infiltration or nerve block,Spinal anesthesia,Epidural anesthesia
Posimir (bupivacaine) is administered as a single intra-articular injection into the subacromial space following arthroscopic shoulder surgery. The recommended adult dose is 5 m L (66 mg) of the 1.32% solution.
1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).
Terminal elimination half-life is approximately 27 hours (range 16-38 hours), supporting once-daily dosing in clinical use.
Terminal half-life 2.5-3.5 hours in adults; prolonged to 4-6 hours in hepatic impairment or elderly.
Primarily hepatic via conjugation with glucuronic acid; major metabolite is 4-hydroxybupivacaine. CYP3A4 and CYP1A2 are involved in minor oxidative metabolism.
Hydrolyzed by plasma pseudocholinesterases to para-aminobenzoic acid and diethylaminoethanol.
Primarily hepatic metabolism via CYP3A4 and CYP1A2 to inactive metabolites; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for >90% of total clearance.
Primarily renal excretion of unchanged drug and metabolites (70-80%); minor biliary elimination (10-15%); fecal excretion <5%.
Approximately 97% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
90-95% bound to alpha-1-acid glycoprotein and albumin.
Volume of distribution is approximately 1.9 L/kg, indicating extensive distribution into tissues.
Vd 0.8-1.2 L/kg; extensive tissue distribution (liver, lungs, brain).
Not applicable via oral route; only administered as a local infiltration. Systemic bioavailability after local administration is approximately 100% locally, but systemic levels are low due to slow release from the formulation.
Oral: 30-40% (first-pass metabolism); Intramuscular: 85-95%; Intravenous: 100%.
No dose adjustment is required for mild to moderate renal impairment. Safety and efficacy have not been established in severe renal impairment (GFR <30 m L/min), use with caution.
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation. Monitor for CNS toxicity.
No dose adjustment is required for mild (Child-Pugh A) hepatic impairment. For moderate (Child-Pugh B) impairment, consider cautious use with monitoring for toxicity. Contraindicated in severe (Child-Pugh C) hepatic impairment.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or use alternative agent.
Safety and efficacy in pediatric patients have not been established. No standard dosing guidelines exist.
Local infiltration: 0.5–2% solution, maximum 4.5 mg/kg (without epinephrine) or 7 mg/kg (with epinephrine). For nerve blocks: weight-based dosing, not to exceed adult maximum.
No specific dose adjustment is recommended, but elderly patients may have increased sensitivity and reduced clearance. Use with caution, monitoring for cardiac and neurological toxicity.
Reduce total dose by 20–30% due to decreased clearance and increased sensitivity; monitor for prolonged effect and toxicity.
Not approved for use in: obstetrical paravertebral block, epidural or intrathecal administration. Risk of cardiac arrest and death has been reported with bupivacaine use via these routes.
Not available.
Risk of overdose and toxicity with unintentional intravascular injection or excessive dosing.,Do not use in patients with hypersensitivity to bupivacaine or any amide-type local anesthetic.,Not recommended for patients with severe hepatic impairment.,Safety in pediatric patients not established.,Use with caution in patients with cardiovascular disease, especially those with impaired cardiac conduction.,May cause methemoglobinemia in susceptible patients.,Chondrolysis with intra-articular use (not indicated for such use).
Risk of systemic toxicity if absorbed into circulation,Hypersensitivity to ester-type anesthetics,Potential for methemoglobinemia with high doses,Use with caution in patients with impaired cardiac or hepatic function
Hypersensitivity to bupivacaine or any component of the formulation,Obstetrical paravertebral block,Epidural or intrathecal administration
Hypersensitivity to ester-type anesthetics or para-aminobenzoic acid,Severe hypotension,Bleeding disorders (for spinal/epidural use),Infection at the injection site
No known food interactions. Avoid alcohol for 24 hours post-administration to minimize additive CNS depression.
No known food interactions. Avoid excessive grapefruit or grapefruit juice consumption due to potential CYP3A4 inhibition.
POSIMIR (bupivacaine) is classified as FDA Pregnancy Category C. Animal studies have shown fetal harm, but adequate human studies are lacking. First trimester: Risk of teratogenicity is unknown; bupivacaine crosses the placenta. Second and third trimesters: Potential for fetal bradycardia, CNS depression, and neurobehavioral effects. Use only if benefit outweighs risk.
Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in first trimester if possible.
Bupivacaine is excreted in breast milk in small amounts. The milk-to-plasma ratio (M/P) is approximately 0.3. The relative infant dose is estimated to be <2% of maternal weight-adjusted dose. Generally considered compatible with breastfeeding, but caution is advised in infants with impaired hepatic function.
Excreted in breast milk in low amounts; M/P ratio not established. Consider risk-benefit; monitor infant for central nervous system depression.
No specific dose adjustments are recommended for POSIMIR in pregnancy. However, physiological changes (increased plasma volume, altered hepatic metabolism) may affect bupivacaine pharmacokinetics, potentially increasing systemic absorption. Use lowest effective dose and monitor for signs of toxicity.
No specific dose adjustments required; pharmacokinetics may be altered but clinical significance unclear.
POSIMIR (bupivacaine) is a long-acting, non-opioid local analgesic administered via infiltration into the surgical site. Its liposomal bupivacaine formulation provides up to 72 hours of analgesia. Do not use for intra-articular, epidural, or intrathecal administration; risk of chondrolysis and nerve injury. Avoid concomitant use with other local anesthetics. Monitor for signs of systemic toxicity (e.g., CNS excitation, cardiac depression). Not recommended in patients with hepatic impairment or myasthenia gravis.
Alphacaine Hydrochloride is an amide-type local anesthetic similar to lidocaine. Onset of action is 2-5 minutes with duration of 30-120 minutes depending on concentration and use of epinephrine. It is hepatically metabolized (CYP3A4) and renally excreted. Dose adjustment required in hepatic impairment. Risk of methemoglobinemia, especially in infants and patients on sulfonamides. Do not exceed maximum doses: 4.5 mg/kg plain, 7 mg/kg with epinephrine.
POSIMIR is a long-acting anesthetic injected at the surgical site to reduce pain for up to 3 days.,Do not drive or operate machinery for at least 48 hours after administration due to potential dizziness or sedation.,Report any signs of allergic reaction: rash, itching, swelling, or difficulty breathing.,Avoid applying heat or ice directly to the injection site unless advised by your surgeon.,You may still feel some sensation; use prescribed rescue analgesics as needed.,Do not use additional numbing creams or sprays near the surgical site.,Contact your doctor if you experience severe headache, blurred vision, or ringing in ears.,If you are pregnant or breastfeeding, discuss risks with your healthcare provider.
Avoid alcohol consumption for 24 hours after procedure.,Inform your doctor if you have liver disease, heart block, or history of methemoglobinemia.,Do not drive or operate machinery until effects wear off.,Report numbness, tingling, or twitching immediately.,For dental procedures: avoid eating until numbness resolves to prevent injury.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POSIMIR vs ALPHACAINE HYDROCHLORIDE, answered by our medical review team.
POSIMIR is a Local Anesthetic that works by Bupivacaine, the active ingredient in POSIMIR, is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. POSIMIR is a bupivacaine extended-release liposomal formulation designed for sustained release at the surgical site.. ALPHACAINE HYDROCHLORIDE is a Local Anesthetic that works by Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POSIMIR and ALPHACAINE HYDROCHLORIDE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POSIMIR is: Posimir (bupivacaine) is administered as a single intra-articular injection into the subacromial space following arthroscopic shoulder surgery. The recommended adult dose is 5 m L (66 mg) of the 1.32% solution.. The standard adult dose of ALPHACAINE HYDROCHLORIDE is: 1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POSIMIR and ALPHACAINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POSIMIR is classified as Category C. POSIMIR (bupivacaine) is classified as FDA Pregnancy Category C. Animal studies have shown fetal harm, but adequate human studies are lacking. First trimester: Risk of teratogenici. ALPHACAINE HYDROCHLORIDE is classified as Category C. Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.